$46 Million Financing to Advance Multi-omics Product Pipeline

PrognomiQ Announces $46 Million Financing to Advance Development of its Multi-omics Product Pipeline for Early Detection and Treatment of Cancer

PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases – today announced it has raised $46 million in financing.

Read the full article here.

Share this page:

January 8, 2025

PrognomiQ Appoints Joel Kaufman as Chief Financial Officer

November 5, 2024

PrognomiQ Announces $34 Million Series D Financing to Advance Development of Early Detection Test for Lung Cancer with Multi-omics Platform

January 8, 2024

PrognomiQ’s Latest Research Demonstrates the Potential of its Multi-omics Liquid Biopsy Platform in Early-Stage Detection of Lung Cancer

NEWS & RESOURCES

PrognomiQ Announces $46 Million Financing to Advance Development of its Multi-omics Product Pipeline for Early Detection and Treatment of Cancer

Related Articles